On Monday, Halozyme Therapeutics Inc (NASDAQ: HALO) opened higher 2.31% from the last session, before settling in for the closing price of $57.15. Price fluctuations for HALO have ranged from $33.15 to $65.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 41.16%. Company’s average yearly earnings per share was noted 42.35% at the time writing. With a float of $125.85 million, this company’s outstanding shares have now reached $126.77 million.
The extent of productivity of a business whose workforce counts for 373 workers is very important to gauge. In terms of profitability, gross margin is 78.34%, operating margin of 50.35%, and the pretax margin is 50.68%.
Halozyme Therapeutics Inc (HALO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Halozyme Therapeutics Inc is 1.09%, while institutional ownership is 99.27%. The most recent insider transaction that took place on Oct 15 ’24, was worth 537,469. In this transaction SVP, CHIEF TECHNICAL OFFICER of this company sold 10,000 shares at a rate of $53.75, taking the stock ownership to the 173,756 shares. Before that another transaction happened on Oct 16 ’24, when Company’s SVP, CHIEF TECHNICAL OFFICER sold 10,000 for $53.26, making the entire transaction worth $532,590. This insider now owns 173,756 shares in total.
Halozyme Therapeutics Inc (HALO) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 0.82 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.82) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.35% per share during the next fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
Check out the current performance indicators for Halozyme Therapeutics Inc (HALO). In the past quarter, the stock posted a quick ratio of 9.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.87. Likewise, its price to free cash flow for the trailing twelve months is 21.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.02, a number that is poised to hit 1.17 in the next quarter and is forecasted to reach 4.60 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
The latest stats from [Halozyme Therapeutics Inc, HALO] show that its last 5-days average volume of 1.74 million was superior to 1.29 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 76.65%. Additionally, its Average True Range was 2.02.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 59.13%, which indicates a significant decrease from 91.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.11% in the past 14 days, which was higher than the 38.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.88, while its 200-day Moving Average is $47.97. Now, the first resistance to watch is $59.63. This is followed by the second major resistance level at $60.80. The third major resistance level sits at $62.20. If the price goes on to break the first support level at $57.06, it is likely to go to the next support level at $55.66. The third support level lies at $54.49 if the price breaches the second support level.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
There are currently 126,678K shares outstanding in the company with a market cap of 8.41 billion. Presently, the company’s annual sales total 829,250 K according to its annual income of 281,590 K. Last quarter, the company’s sales amounted to 231,350 K and its income totaled 93,250 K.
